CO4930274A1 - Tiazol bencenosulfonamidas como agonistas b3 para el trata- miento de la diabetes y la obesidad - Google Patents

Tiazol bencenosulfonamidas como agonistas b3 para el trata- miento de la diabetes y la obesidad

Info

Publication number
CO4930274A1
CO4930274A1 CO98003945A CO98003945A CO4930274A1 CO 4930274 A1 CO4930274 A1 CO 4930274A1 CO 98003945 A CO98003945 A CO 98003945A CO 98003945 A CO98003945 A CO 98003945A CO 4930274 A1 CO4930274 A1 CO 4930274A1
Authority
CO
Colombia
Prior art keywords
oxygen
sulfur
halogen
nitrogen
heterocyclic ring
Prior art date
Application number
CO98003945A
Other languages
English (en)
Inventor
Robert J Mathvink
Emma R Parmee
Samuel Tolman
Ann E Weber
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CO4930274A1 publication Critical patent/CO4930274A1/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D1/00—Processes for applying liquids or other fluent materials
    • B05D1/30—Processes for applying liquids or other fluent materials performed by gravity only, i.e. flow coating
    • B05D1/305—Curtain coating
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D3/00—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials
    • B05D3/04—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by exposure to gases
    • B05D3/0433—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by exposure to gases the gas being a reactive gas
    • B05D3/044—Pretreatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto que tiene la fórmula I:en donde X es (1) un enlace,(2) alquileno C1 -C3 , opcionalmente substituido con 1 ó 2 grupos seleccionados entre metil y halógeno.(3) alquileno C1 -C3 en donde dicho alquileno contiene un oxígeno, opcionalmente sustituido con 1 ó 2 grupos seleccionados entre metil y halógeno.m va de 0 a 5;A es (1) fenil,(2) un anillo heterocíclico de 5 ó 6 miembros con 1 a 4 heteroátomos seleccionados entre oxígeno, azufre y nitrógeno,(3) un anillo bencénico fusionado a un anillocarbocíclico C5 -C10 ,(4) un anillo heterocíclico de 5 ó 6 miembros que tiene de 1 a 4 heteroátomos seleccionados entre oxígeno, azufre y nitrógeno fusionado a anillo heterocíclico de 5 ó 6 miembros con 1 a 4 heteroátomos seleccionados entre oxígeno, azufre ynitrógeno, o(5) un anillo heterocíclico de 5 ó 6 miembros con 1 a 4 heteroátomos seleccionados entre oxígeno, azufre y nitrógeno fusionado a un anillo carbocíclico C5 -C10 ;R1 es (1) alquil C1 -C10 opcionalmente sustituido con hasta 5 grupos seleccionados de un conjunto conformado por:(a) hidroxi,(b) halógeno,(c) ciano,(d) QR2 ,(e) cicloalquil C3 -C8 ,(f) A, opcionalmente sustituido con hasta 5 grupos seleccionados entre halógeno, alquil C1 -C10 y alcoxi C1 -C10 ,(g) Q´COR3 ,(h) S(O)n R3 , en donde n va de O - 2,...
CO98003945A 1997-01-28 1998-01-28 Tiazol bencenosulfonamidas como agonistas b3 para el trata- miento de la diabetes y la obesidad CO4930274A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3676097P 1997-01-28 1997-01-28

Publications (1)

Publication Number Publication Date
CO4930274A1 true CO4930274A1 (es) 2000-06-27

Family

ID=21890469

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98003945A CO4930274A1 (es) 1997-01-28 1998-01-28 Tiazol bencenosulfonamidas como agonistas b3 para el trata- miento de la diabetes y la obesidad

Country Status (3)

Country Link
US (1) US6011048A (es)
CO (1) CO4930274A1 (es)
ZA (1) ZA98647B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2398199A1 (en) * 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha Novel therapeutic agents that use a .beta.3 agonist
DK1283830T3 (da) * 2000-05-08 2008-08-25 Hoffmann La Roche Para-amin-substituerede phenylamidglucokinase-aktivatorer
CA2415331A1 (en) * 2000-07-13 2002-01-24 Eli Lilly And Company Beta3 adrenergic agonists
CA2421594A1 (en) 2000-11-10 2002-05-16 John Arnold Werner 3-substituted oxindole beta 3 agonists
WO2003016307A1 (en) * 2001-08-14 2003-02-27 Eli Lilly And Company β3 ADRENERGIC AGONISTS
AU2002318206A1 (en) * 2001-08-14 2003-03-03 Jolie Anne Bastian 3-substituted oxindole beta-3 agonists
ATE297925T1 (de) * 2001-11-20 2005-07-15 Lilly Co Eli 3-substituierte oxindol beta 3 agonisten
DE60225174T2 (de) * 2001-11-20 2009-02-12 Eli Lilly And Co., Indianapolis Beta-3 adrenergische agonisten
AU2002349705A1 (en) * 2001-12-03 2003-06-17 Japan Tobacco Inc. Azole compound and medicinal use thereof
US7009060B2 (en) * 2002-01-11 2006-03-07 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
CA2478183C (en) * 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
AU2003234709A1 (en) * 2002-04-11 2003-10-27 Carbomer Fluorinated or paramagnetic alginate polymer, annexin paramagnetic conjugate, and their use as contrasting agent in mri
US6911457B2 (en) 2002-04-11 2005-06-28 Carbomer, Inc. Diabetes imaging probes
US20040110803A1 (en) * 2002-09-13 2004-06-10 Hossein Dovlatabadi Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
TW200500362A (en) * 2003-04-09 2005-01-01 Japan Tobacco Inc 5-membered heteroaromatic ring compound and pharmaceutical use thereof
US7820704B2 (en) * 2004-04-20 2010-10-26 Transtech Pharma, Inc. Substituted heteroaryl derivatives, compositions, and methods of use
AU2008233232A1 (en) * 2007-03-29 2008-10-09 Merck Sharp & Dohme Corp. Combination therapy for the treatment-of lower urinary tract symptoms
WO2010025142A1 (en) * 2008-08-29 2010-03-04 Transtech Pharma, Inc. Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091749A3 (en) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US5705515A (en) * 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity

Also Published As

Publication number Publication date
ZA98647B (en) 1998-07-28
US6011048A (en) 2000-01-04

Similar Documents

Publication Publication Date Title
CO4930274A1 (es) Tiazol bencenosulfonamidas como agonistas b3 para el trata- miento de la diabetes y la obesidad
CO5021135A1 (es) Compuestos quimicos
HUP9701169A2 (hu) Cikloalkano-piridin-származékok, intermedierjeik, előállításuk és alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
AR013693A1 (es) Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
CO4940442A1 (es) Derivados de 4-bromo o 4-yodo fenilamino acido benzhidroxamico
BR0305842A (pt) Mistura curável, e, método
PE20020254A1 (es) Derivados de piridina
ID29452A (id) 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus
CO5550398A2 (es) 7-aminotriazolpirimidinas, proceso e intermedios para su preparacion, composiciones que las comprenden y su uso para controlar hongos dañinos
ES2188016T3 (es) Derivaqdo de benzamidoxima, productos intermedios y procedimiento para su obtencion y su empleo como fungicidas.
CO5450245A1 (es) Compuestos quimicos con actividad doble, procedimientos para su preparacion y composiciones farmaceuticas
ECSP941066A (es) Derivados de 1.5 benzodiazepina
PE20061335A1 (es) Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c
ES2115391T3 (es) Catalizadores y procedimiento para la polimerizacion de olefinas.
PE20020195A1 (es) AGONISTAS ß3 ADRENERGICOS
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
DK0651737T3 (da) O-Benzyloximetherderivater samt deres anvendelse som pesticider
AR018917A1 (es) Compuestos derivados de adenosina que son agonistas en el receptor adenosina a1, proceso para su preparacion, composiciones farmaceuticas que los contienen.
CO5160347A1 (es) Derivados de acido carbamico
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
BR8704389A (pt) Composicao de pintura e processo para a protecao de uma substancia de pintura
CO5601021A2 (es) Derivados de quinazolinona, composiciones farmaceuticas que los contienen y su proceso de preparacion y su uso como antagonistas cb
ATE137805T1 (de) Verfahren zur erhöhung von chemilumineszenz
PE20040528A1 (es) Inhibidores de la peptido-deformilasa